AstraZeneca has agreed to acquire Belgium-based EsoBiotec for up to $1 billion, with an initial payment of $425 million and additional milestone-based payments of up to $575 million.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.